# Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

> **NCT04390152** · PHASE1,PHASE2 · TERMINATED · sponsor: **BioXcellerator** · enrollment: 6 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** Wharton's jelly derived Mesenchymal stem cells.
- **DRUG:** Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)

## Key facts

- **NCT ID:** NCT04390152
- **Lead sponsor:** BioXcellerator
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-13
- **Primary completion:** 2022-03-03
- **Final completion:** 2022-03-03
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Stopped by the IP, because the first 6 patients recruited had died and it was unknown if it represented any safety risk or if the sample was insufficient to evaluate the study hypotesis.
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04390152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04390152, "Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04390152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*